Stefan Kasper
Impact in
- Otorhinolaryngology top 0.2%
- Head and Neck Cancer Studies
- Oncology top 0.5%
- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research
Papers in
- Oncology 70
- Colorectal Cancer Treatments and Studies 28
- Cancer Immunotherapy and Biomarkers 17
- Peptidase Inhibition and Analysis 10
-
- Head and Neck Cancer Studies 15
- Co-authors
- Martin Schüler (40 shared papers)Frank Breitenbuecher (16 shared papers)Thomas Fischer (7 shared papers)Thomas Kindler (7 shared papers)Florian Heinrich Heidel (5 shared papers)Boyka Markova (6 shared papers)Sandra Hoffarth (4 shared papers)Kurt Werner Schmid (15 shared papers)
- Journals
- Annals of Oncology (14 papers)European Journal of Cancer (13 papers)Journal of Cancer Research and Clinical Oncology (8 papers)Journal of Nuclear Medicine (7 papers)ESMO Open (6 papers)
- Partner nations
- GermanyUnited StatesFrance
In The Last Decade
Stefan Kasper
130 papers receiving 10.0k citations
Stefan Kasper's Hit Papers
Peers
Comparison fields: 5 of 118
- Otorhinolaryngology 1.6k
- Oncology 4.5k
- Pulmonary and Respiratory Medicine 2.6k
- Immunology 1.6k
- Gastroenterology 320
Countries citing papers authored by Stefan Kasper
This map shows the geographic impact of Stefan Kasper's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stefan Kasper with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stefan Kasper more than expected).
Fields of papers citing papers by Stefan Kasper
This network shows the impact of papers produced by Stefan Kasper. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stefan Kasper. The network helps show where Stefan Kasper may publish in the future.
Co-authors
The 25 scholars most cited alongside Stefan Kasper, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 141 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck Hit paper breakdown → | 2016 | 4042 |
| 2 | Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial Hit paper breakdown → | 2019 | 1869 |
| 3 | Nivolumab vs investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression Hit paper breakdown → | 2018 | 633 |
| 4 | Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial Hit paper breakdown → | 2017 | 347 |
| 5 | 2005 | 239 | |
| 6 | Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study Hit paper breakdown → | 2023 | 219 |
| 7 | 2022 | 193 | |
| 8 | 2017 | 173 | |
| 9 | 2019 | 126 | |
| 10 | Durvalumab with or without tremelimumab versus the EXTREME regimen as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck: KESTREL, a randomized, open-label, phase III study Hit paper breakdown → | 2022 | 111 |
| 11 | 2013 | 109 | |
| 12 | 2009 | 108 | |
| 13 | 2014 | 91 | |
| 14 | 2020 | 84 | |
| 15 | 2019 | 83 | |
| 16 | 2018 | 81 | |
| 17 | 2012 | 75 | |
| 18 | 2018 | 64 | |
| 19 | 2016 | 60 | |
| 20 | 2022 | 58 |
About Stefan Kasper
Stefan Kasper is a scholar working on Oncology, Otorhinolaryngology, Surgery, Pulmonary and Respiratory Medicine and Cancer Research, having authored 141 papers that have together received 10.2k indexed citations. Recurring topics across this work include Colorectal Cancer Treatments and Studies (28 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (18 papers), Cancer Immunotherapy and Biomarkers (17 papers), Head and Neck Cancer Studies (15 papers), Lung Cancer Treatments and Mutations (14 papers), Peptidase Inhibition and Analysis (10 papers), Chronic Myeloid Leukemia Treatments (8 papers) and Gastric Cancer Management and Outcomes (7 papers). The work is most often cited by research in Otorhinolaryngology (1.6k citations), Oncology (4.5k citations), Pulmonary and Respiratory Medicine (2.6k citations), Immunology (1.6k citations) and Gastroenterology (320 citations). Stefan Kasper has collaborated with scholars based in Germany, United States and France. Frequent co-authors include Martin Schüler, Frank Breitenbuecher, Thomas Fischer, Thomas Kindler, Florian Heinrich Heidel, Boyka Markova, Sandra Hoffarth, Kurt Werner Schmid, Christoph Huber and Daniel Bernhard Lipka. Their work appears in journals such as Annals of Oncology, European Journal of Cancer, Journal of Cancer Research and Clinical Oncology, Journal of Nuclear Medicine and ESMO Open.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.